Skip to content

Advertisement

Open Peer Review Reports for: Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
5 May 2018 Submitted Original manuscript
5 Jul 2018 Reviewed Reviewer Report - Joung Jang
17 Sep 2018 Reviewed Reviewer Report - Junji Furuse
17 Oct 2018 Reviewed Reviewer Report - Masashi Kanai
29 Nov 2018 Author responded Author comments - Markus Moehler
Resubmission - Version 2
29 Nov 2018 Submitted Manuscript version 2
6 Dec 2018 Reviewed Reviewer Report - Masashi Kanai
12 Dec 2018 Author responded Author comments - Markus Moehler
Resubmission - Version 3
12 Dec 2018 Submitted Manuscript version 3
Publishing
13 Dec 2018 Editorially accepted
11 Jan 2019 Article published 10.1186/s12885-018-5223-7

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement